Secukinumab Trial Targets Relapsed Polymyalgia Rheumatica - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Secukinumab Trial Targets Relapsed Polymyalgia Rheumatica

Phase 3 findings address remission durability and glucocorticoid use in patients who relapsed during prednisone tapering.

  • By

  • Kathryn Wighton

  • July 31, 2026

  • 5 min

Share

  • 1

    In the REPLENISH trial, 41% of patients receiving secukinumab achieved sustained remission at 52 weeks compared to 20% receiving placebo.

  • 2

    The trial enrolled 381 patients aged 50 or older with relapsed polymyalgia rheumatica across 148 sites in 28 countries.

  • 3

    Complete sustained remission occurred in 28% of the secukinumab 300 mg group, 25% in the 150 mg group, and 5% in the placebo group.

  • 4

    Patients receiving secukinumab had lower annual cumulative glucocorticoid exposure, with doses 20% to 23% lower than the placebo group.

  • 5

    Serious adverse events occurred in 14-16% of patients in the secukinumab groups, with fungal infections reported more frequently than in the placebo group.

Original Source(s)

Secukinumab Trial Targets Relapsed Polymyalgia Rheumatica

  • by Kathryn Wighton

  • July 31, 2026

Related Content

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Side Effects: Bro Science, Actually

Creatine's ATP-buffering trick isn't just for biceps. In mice, it juices up dendritic cells' energy supply, sharpening T-cell priming and shrinking tumors on daily injections. Human DCs got the memo too, at least in a dish. Early days, but a fun plot twist for gym-bag chemistry.

Global research landscape and emerging trends of tertiary lymphoid structures in autoimmune diseases: a bibliometric analysis